Refocusing the World Health Organization's Model List of Essential Medicines on the needs of low and middle income countries
BMJ
.
2024 Apr 16:385:e077776.
doi: 10.1136/bmj-2023-077776.
Authors
Veronika J Wirtz
1
,
Andrew L Gray
2
,
Sangeeta Sharma
3
,
Jing Sun
4
,
Hans V Hogerzeil
5
Affiliations
1
Department of Global Health, Boston University School of Public Health, Boston, USA vwirtz@bu.edu.
2
Division of Pharmacology, Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Durban, South Africa.
3
Department of Neuropsychopharmacology, Institute of Human Behaviour and Allied Sciences (IHBAS), Delhi, India.
4
School of Health Policy and Management, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
5
University Medical Centre Groningen, University of Groningen, Netherlands.
PMID:
38626944
DOI:
10.1136/bmj-2023-077776
No abstract available
MeSH terms
Developing Countries*
Drugs, Essential*
Global Health
Health Services Accessibility
Humans
World Health Organization
Substances
Drugs, Essential